MIST - Milestone Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

PR Newswire

MONTREAL and CHARLOTTE, N.C., Sept. 7, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 23 ^rd Annual Global Investment Conference being held virtually on September 13-15, 2021 .

The prerecorded fireside chat will become available on Monday, September 13, 2021 at 7:00am ET and can be accessed in the News & Events section of Milestone's website at www.milestonepharma.com . An archived replay of the fireside chat will be available on the same website 90 days following the presentation.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone's lead product candidate etripamil is currently in a Phase 3 clinical-stage program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and in a Phase 2 proof-of-concept trial for the treatment of patients with atrial fibrillation and rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and the United States . For more information, visit www.milestonepharma.com and follow the Company on Twitter at @MilestonePharma.

Contact

David Pitts
Argot Partners
212-600-1902
david@argotpartners.com

SOURCE Milestone Pharmaceuticals, Inc.